Zacks Premium服务 - Zacks Premium提供每日更新的Zacks Rank和Zacks Industry Rank数据 帮助投资者更自信地决策 [1] - 服务包含Zacks 1 Rank List、股票研究报告和高级选股工具 [1] - 提供Zacks Style Scores作为补充指标 辅助筛选未来30天可能跑赢市场的股票 [1][2] Zacks Style Scores评分体系 - 评分分为A/B/C/D/F五档 评分越高股票表现越优 [3] - 价值评分(Value Score)关注P/E、PEG等估值指标 筛选价格低于内在价值的股票 [3] - 成长评分(Growth Score)分析盈利预测和历史数据 识别长期增长潜力股 [4] - 动量评分(Momentum Score)结合周价格变动和盈利预测月度变化 捕捉趋势机会 [5] - VGM评分综合三大评分 筛选兼具价值、成长和动量优势的股票 [6] Zacks Rank评级系统 - 基于盈利预测修正的专有评级模型 自1988年来1评级股票年均回报达25.41% [7][8] - 每日有200+家公司获Strong Buy评级 600+家获Buy评级 [8] - 建议优先选择1/2评级且Style Scores为A/B的股票 [9] - 即使Style Scores高 但4/5评级股票因盈利预测下滑仍存在下跌风险 [10] 案例公司：Qiagen (QGEN) - 荷兰核酸分离纯化技术龙头 拥有500+专利产品和自动化解决方案 [11] - 当前Zacks Rank为2(Buy) VGM评分为B 成长评分为B [12] - 2025财年盈利预测同比增长7.3% 过去60天获9位分析师上调预测 [12] - 共识盈利预期上调0.07美元至2.34美元/股 历史盈利超预期幅度达4.9% [12][13]

Key Takeaways QGEN partners with GENCURIX to develop oncology assays for the QIAcuityDx digital PCR platform. The pact launches QGEN's QIAcuityDx Partnering Program to broaden its clinical assay ecosystem. GENCURIX will develop and seek approval for assays, which QGEN will market through its global network.QIAGEN N.V. (QGEN) has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics compa ...

Key Takeaways Incyte rose 5.1% after partnering with QIAGEN to advance diagnostics for rare blood cancers. QIAGEN will create a next-generation sequencing panel focused on mutCALR for MPNs patient selection. Early data shows INCY's INCA033989 yields strong responses and targets mutCALR while sparing healthy cells.Shares of Incyte (INCY) gained 5.1% on Monday following the announcement of a global partnership with Netherlands-based QIAGEN N.V. (QGEN) . The collaboration aims to develop a novel diagnostic p ...

Key Takeaways QGEN is expanding key platforms with FDA-cleared panels and new digital PCR assay launches. Strategic deals with Eli Lilly, AstraZeneca, and others are fueling QGEN's diagnostic innovations. QGEN maintains solid solvency, with $638.8M in cash and just $56M in current debt as of Q1 2025.QIAGEN N.V. (QGEN) is well-poised to grow in the upcoming quarters, courtesy of substantial investment in research and development (R&D) for the menu expansion of its key platforms. Expanding through partnersh ...

Qiagen (QGEN) FY Conference June 09, 2025 09:00 AM ET Speaker0 Hi, good morning, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of being joined by Roland Saker, CFO and John Gallardi, Head of IR. Roland, John, thanks for being here. Speaker1 Thank you. Speaker2 Thank you. Speaker0 Maybe we could start out, just given the current environment we're in, which is continues to be challenging, maybe just talk through sort of the durability of your end ma ...

Qiagen (QGEN) 2025 Conference June 05, 2025 09:55 AM ET Speaker0 Okay. Thanks. Speaker1 I think, Roland, maybe I'll just start off with a higher level question. You've done a lot in terms of reshaping the portfolio. You're buying stock. You've got, you know, expanding margins. You're you're doing all the right things. I think are there areas areas you think you could be doing more and what do you Speaker2 think is Speaker1 most underappreciated right now? Speaker2 First thing that I'm going to do is buy a n ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style S ...

Key Takeaways QGEN partners with Tracer and Foresight to advance MRD testing in oncology clinical trials. New alliances support decentralized, non-invasive diagnostics using QIAGEN's QIAcuity dPCR and ctDNA tests. The partnerships aim to broaden clinical access and enhance QGEN's leadership in personalized cancer care.QIAGEN N.V. (QGEN) announced the expansion of its oncology diagnostics portfolio with two strategic partnerships. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics ...

BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.Th ...

QIAGEN N.V. (QGEN) recently entered into a commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays, to expand the availability of dPCR assays for oncology research applications. The latest partnership is likely to expand QIAGEN’s position in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research.QGEN Stock’s Likely Trend Following the NewsFollowing the announcement, shares of QIAGEN remain ...